Literature DB >> 11940704

Long-term survival after gene therapy for a recurrent glioblastoma.

C A Valéry1, D Seilhean, O Boyer, B Marro, J-J Hauw, J-L Kemeny, C Marsault, J Philippon, D Klatzmann.   

Abstract

A patient presenting with a recurrent glioblastoma (GBM) survived 3 years after suicide gene therapy and finally died of a disseminated breast cancer with no indication of tumor recurrence on MRI. Postmortem analysis showed no evidence of recurrence of the GBM, neither near the initial tumor localization nor in any other area of the brain. Such an evolution is unusual in the course of this disease and may suggest in this particular case a cure of the GBM.

Entities:  

Mesh:

Year:  2002        PMID: 11940704     DOI: 10.1212/wnl.58.7.1109

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Radiolabeling strategies for radionuclide imaging of stem cells.

Authors:  Esther Wolfs; Catherine M Verfaillie; Koen Van Laere; Christophe M Deroose
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

2.  Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).

Authors:  Jessica M Grunda; L Burton Nabors; Cheryl A Palmer; David C Chhieng; Adam Steg; Tom Mikkelsen; Robert B Diasio; Kui Zhang; David Allison; William E Grizzle; Wenquan Wang; G Yancey Gillespie; Martin R Johnson
Journal:  J Neurooncol       Date:  2006-06-14       Impact factor: 4.130

Review 3.  Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology.

Authors:  E Antonio Chiocca; William C Broaddus; George T Gillies; Therese Visted; Martine L M Lamfers
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 4.  Recent trends in targeted anticancer prodrug and conjugate design.

Authors:  Yashveer Singh; Matthew Palombo; Patrick J Sinko
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

5.  Delayed response and survival from NovoTTF-100A in recurrent GBM.

Authors:  J Lee Villano; Leena E Williams; Karriem S Watson; Nandini Ignatius; Marquess T Wilson; Tibor Valyi-Nagy; Edward A Michals; Herbert H Engelhard
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

Review 6.  Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

Authors:  Syed R Husain; Raj K Puri
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

7.  Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis.

Authors:  Sudheer R Thumma; Robert K Fairbanks; Wayne T Lamoreaux; Alexander R Mackay; John J Demakas; Barton S Cooke; Ameer L Elaimy; Peter W Hanson; Christopher M Lee
Journal:  World J Surg Oncol       Date:  2012-05-03       Impact factor: 2.754

8.  Dicistronic MLV-retroviral vectors transduce neural precursors in vivo and co-express two genes in their differentiated neuronal progeny.

Authors:  Edmund A Derrington; Marcelo López-Lastra; Jean-Luc Darlix
Journal:  Retrovirology       Date:  2005-09-29       Impact factor: 4.602

Review 9.  Imaging in gene therapy of patients with glioma.

Authors:  A H Jacobs; J Voges; L W Kracht; C Dittmar; A Winkeler; A Thomas; K Wienhard; K Herholz; W D Heiss
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.